Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetravalent dengue vaccine + hepatitis A vaccine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration or co-formulation of a tetravalent dengue vaccine and a hepatitis A vaccine. The dengue component is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4), typically utilizing a live-attenuated viral platform such as the chimeric yellow fever-dengue virus (CYD-TDV). The hepatitis A component is an inactivated whole-virus vaccine intended to prevent infection by the hepatitis A virus. Clinical studies, such as those conducted by Sanofi Pasteur, have evaluated the safety and immunogenicity of these vaccines when administered concomitantly to simplify immunization schedules in regions where both diseases are endemic. The combination aims to maintain the high seroconversion rates of the individual vaccines while reducing the number of clinical visits required for full immunization.
- Other names
- CYD-TDV + HAVDengvaxia + HavrixDengvaxia + Vaqtatetravalent dengue vaccine and hepatitis A vaccine combination
02
Targets
Dengue virus type 1 prM/E glycoproteinDengue virus type 2 precursor membrane and envelope proteinsHepatitis A virus capsid proteinDengue virus type 3 premembrane and envelope proteinsPRR (Pattern recognition receptors)
Beyond the preview
Go deeper on tetravalent dengue vaccine + hepatitis A vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetravalent dengue vaccine + hepatitis A vaccine.